Magic™ Humanized OX40 Immune Checkpoint Knock-In Mice

  • Check with publisher
  • Published date: September 30, 2019
    • Shirley, New York, United States

Administration of anti-OX40 increases proliferation of peripheral blood CD4+ and CD8+ T cells, increases responses to recall and naïve reporter Ags, and increases endogenous tumor-specific immune responses. Several agonistic anti-OX40 antibodies are now tested in early phase cancer clinical trials. Accumulating preclinical evidence supports their application value in cancer treatment. https://www.creative-biolabs.com/drug-discovery/therapeutics/magic-humanized-ox40-immune-checkpoint-knock-in-mice.htm

Result 0 votes
Jerry Carter
0 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • Magic™ Humanized CD27 Immune Checkpoint Knock-In Mice

    Magic™ Humanized CD27 Immune Checkpoint Knock-In Mice

    Biology & Physiology Shirley (New York) September 30, 2019 Check with publisher

    The activity of CD27 is restricted by the transient availability of its ligand CD70/TNFSF7, which is constitutively expressed on medullary thymic epithelial cells (mTECs) and dendritic cells. Apart from this, CD70/TNFSF7 is specifically expressed aft...

  • Magic™ Humanized SIRPα Immune Checkpoint Knock-In Mice

    Magic™ Humanized SIRPα Immune Checkpoint Knock-In Mice

    Biology & Physiology Shirley (New York) September 30, 2019 Check with publisher

    In a wide variety of preclinical models, therapies that block the CD47/SIRPα axis stimulate phagocytosis of cancer cells in vitro and anti-tumor immune responses in vivo. Nowadays, many therapeutics targeting the CD47/SIRPα axis are under preclinical...

  • Magic™ Humanized CD28 Immune Checkpoint Knock-In Mice

    Magic™ Humanized CD28 Immune Checkpoint Knock-In Mice

    Biology & Physiology Shirley (New York) September 30, 2019 Check with publisher

    CD28 and CTLA4 are highly homologous and compete for the same ligands [B7-1 (CD80) and B7-2 (CD86)]. The affinity of CTLA4 binding to these ligands is higher than CD28, which enables CTLA4 to compete with CD28 for ligands and suppress effector T cell...